92,450 Shares in Ingevity Corporation $NGVT Acquired by Trillium Asset Management LLC

Trillium Asset Management LLC bought a new stake in shares of Ingevity Corporation (NYSE:NGVT) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 92,450 shares of the company’s stock, valued at approximately $6,903,000. Trillium Asset Management LLC owned about 0.27% of Ingevity as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Assetmark Inc. raised its holdings in shares of Ingevity by 9.6% in the first quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after acquiring an additional 139 shares during the last quarter. Advisory Services Network LLC boosted its stake in shares of Ingevity by 4.4% during the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock valued at $383,000 after acquiring an additional 293 shares during the last quarter. Amundi increased its position in Ingevity by 4.8% during the 3rd quarter. Amundi now owns 6,626 shares of the company’s stock worth $364,000 after purchasing an additional 302 shares in the last quarter. Isthmus Partners LLC increased its position in Ingevity by 0.5% during the 4th quarter. Isthmus Partners LLC now owns 72,245 shares of the company’s stock worth $4,275,000 after purchasing an additional 375 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after purchasing an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Wall Street Analysts Forecast Growth

NGVT has been the topic of several analyst reports. Weiss Ratings raised shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $80.00.

Ingevity Trading Down 2.3%

Shares of NGVT stock opened at $69.54 on Friday. The firm has a market cap of $2.39 billion, a P/E ratio of 47.31 and a beta of 1.16. Ingevity Corporation has a 1-year low of $45.85 and a 1-year high of $79.29. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. The firm’s 50-day simple moving average is $73.88 and its 200-day simple moving average is $71.84.

Ingevity (NYSE:NGVT) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, equities analysts forecast that Ingevity Corporation will post 5.4 EPS for the current year.

Insider Buying and Selling at Ingevity

In other news, SVP Terrance M. Dyer sold 496 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the sale, the senior vice president directly owned 7,202 shares of the company’s stock, valued at $493,264.98. The trade was a 6.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David H. Li sold 5,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $75.83, for a total value of $379,150.00. Following the sale, the chief executive officer owned 120,636 shares of the company’s stock, valued at approximately $9,147,827.88. The trade was a 3.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,297 shares of company stock worth $1,381,452 in the last quarter. 0.88% of the stock is owned by insiders.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.